Tumour cell characteristics and microenvironment composition correspond to clinical presentation in newly diagnosed nodular lymphocyte‐predominant Hodgkin lymphoma

Different studies have characterized the microenvironment and its prognostic impact in classic Hodgkin lymphoma whereas such analyses are pending for nodular lymphocyte‐predominant Hodgkin lymphoma (NLPHL). We thus investigated characteristics of tumour cells and microenvironment in NLPHL and evaluated possible correlations with the clinical presentation. Lymph node samples from 152 NLPHL patients who had first‐line treatment within the randomized German Hodgkin Study Group HD16–HD18 trials were available and analysed with regard to IgD status and nuclear size of the tumour cells as well as presence of PD1‐positive follicular T helper cells and CD163‐positive macrophages in the microenvironment. While large tumour cell nuclei and high numbers of PD1‐positive follicular T helper cells in the microenvironment were more common in patients presenting with early/intermediate stages than in patients with advanced‐stage disease (p < 0.0001, unpaired t‐test; p = 0.0022, Mann–Whitney test), no differences between risk groups were observed in terms of the IgD status of the tumour cells and the content of CD163‐positive macrophages in the microenvironment. PD1‐positive follicular T helper cells were present in both cases with typical and variant growth patterns and rosetting around the tumour cells was observed in 96% of patients, indicating an important role of PD1‐positive follicular T helper cells in NLPHL.

[1]  M. Piel,et al.  T‐cell‐derived Hodgkin lymphoma has motility characteristics intermediate between Hodgkin and anaplastic large cell lymphoma , 2022, Journal of cellular and molecular medicine.

[2]  S. Hartmann,et al.  3D analyses reveal T cells with activated nuclear features in T-cell/histiocyte-rich large B-cell lymphoma , 2022, Modern Pathology.

[3]  A. Rosenwald,et al.  Histopathological growth patterns in patients with advanced nodular lymphocyte‐predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group , 2021, British journal of haematology.

[4]  C. Kobe,et al.  PET-2-guided escalated BEACOPP for advanced nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the randomized German Hodgkin Study Group HD18 study. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  A. van den Berg,et al.  Soluble PD‐L1 is a promising disease biomarker but does not reflect tissue expression in classic Hodgkin lymphoma , 2021, British journal of haematology.

[6]  A. Rosenwald,et al.  PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. , 2021, The Lancet. Oncology.

[7]  A. LaCasce,et al.  Spatial Signatures Identify Immune Escape via PD-1 as a Defining Feature of T-cell/Histiocyte-rich Large B-cell Lymphoma. , 2020, Blood.

[8]  M. Hansmann,et al.  Lymphocyte predominant cells of nodular lymphocyte predominant Hodgkin lymphoma interact with rosetting T cells in an immunological synapse , 2020, American journal of hematology.

[9]  M. Pfreundschuh,et al.  Lymphocyte predominant cells detect Moraxella catarrhalis-derived antigens in nodular lymphocyte-predominant Hodgkin lymphoma , 2020, Nature Communications.

[10]  A. Rosenwald,et al.  The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma , 2019, American journal of hematology.

[11]  A. Rosenwald,et al.  Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  V. Beneš,et al.  JUNB, DUSP2, SGK1, SOCS1 and CREBBP are frequently mutated in T-cell/histiocyte-rich large B-cell lymphoma , 2018, Haematologica.

[13]  N. Johnson,et al.  Distinct 3D Structural Patterns of Lamin A/C Expression in Hodgkin and Reed-Sternberg Cells , 2018, Cancers.

[14]  R. Greil,et al.  PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group , 2017, The Lancet.

[15]  A. Engert,et al.  Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management. , 2017, Hematology. American Society of Hematology. Education Program.

[16]  Neena Kalia,et al.  Biomechanical properties of human T cells in the process of activation based on diametric compression by micromanipulation. , 2017, Medical engineering & physics.

[17]  Peter Bankhead,et al.  QuPath: Open source software for digital pathology image analysis , 2017, Scientific Reports.

[18]  A. van den Berg,et al.  Characterization of the Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma , 2016, International journal of molecular sciences.

[19]  V. Beneš,et al.  Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma , 2016, Leukemia.

[20]  A. Shankar,et al.  Childhood and Adolescent nodular lymphocyte predominant Hodgkin lymphoma ‐ A review of clinical outcome based on the histological variants , 2015, British journal of haematology.

[21]  R. Gascoyne,et al.  Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma , 2015, British journal of haematology.

[22]  A. Rosenwald,et al.  Histopathological features and their prognostic impact in nodular lymphocyte‐predominant Hodgkin lymphoma – a matched pair analysis from the German Hodgkin Study Group (GHSG) , 2014, British journal of haematology.

[23]  G. Slack,et al.  EBV May Be Expressed in the LP Cells of Nodular Lymphocyte–predominant Hodgkin Lymphoma (NLPHL) in Both Children and Adults , 2014, The American journal of surgical pathology.

[24]  A. Rosenwald,et al.  The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). , 2013, Blood.

[25]  R. Gascoyne,et al.  Nodular Lymphocyte Predominant Hodgkin Lymphoma and T Cell/Histiocyte Rich Large B Cell Lymphoma - Endpoints of a Spectrum of One Disease? , 2013, PloS one.

[26]  G. Shivashankar,et al.  Model of T-cell nuclear deformation by the cortical actin layer. , 2013, Biophysical journal.

[27]  C. Wolf‐peeters,et al.  T cell/histiocyte-rich large B-cell lymphoma: an update on its biology and classification , 2011, Virchows Archiv.

[28]  E. Morii,et al.  Prognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma , 2011, Virchows Archiv.

[29]  P. Kamper,et al.  Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin’s lymphoma , 2011, Haematologica.

[30]  A. Tzankov,et al.  Refined Prognostic Role of CD68-Positive Tumor Macrophages in the Context of the Cellular Micromilieu of Classical Hodgkin Lymphoma , 2011, Pathobiology.

[31]  R. Warnke,et al.  Programmed death 1 expression in variant immunoarchitectural patterns of nodular lymphocyte predominant Hodgkin lymphoma: comparison with CD57 and lymphomas in the differential diagnosis. , 2010, Human pathology.

[32]  J. Delabie,et al.  T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response , 2010, Haematologica.

[33]  V. Diehl,et al.  Nodular lymphocyte-predominant Hodgkin lymphoma , 2008, Current hematologic malignancy reports.

[34]  F. Preffer,et al.  Beyond the lymphocyte predominant cell: CD4+CD8+ T-cells in nodular lymphocyte predominant Hodgkin lymphoma , 2008, Leukemia & lymphoma.

[35]  E. Jaffe,et al.  IgD Positive L&H Cells Identify a Unique Subset of Nodular Lymphocyte Predominant Hodgkin Lymphoma , 2006, The American journal of surgical pathology.

[36]  G. Krohne,et al.  The lamin CxxM motif promotes nuclear membrane growth , 2004, Journal of Cell Science.

[37]  Robert Tibshirani,et al.  Characterization of Variant Patterns of Nodular Lymphocyte Predominant Hodgkin Lymphoma with Immunohistologic and Clinical Correlation , 2003, The American journal of surgical pathology.

[38]  V. Diehl,et al.  European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. , 2000, Blood.